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Type II topoisomerases regulate DNA topology by making a double-stranded break in one DNA duplex,
transporting another DNA segment through this break and then resealing it. Bacterial type IIA topoisomerase
inhibitors, such as fluoroquinolones and novel bacterial topoisomerase inhibitors, can trap DNA cleavage
complexes with double- or single-stranded cleaved DNA. To study the mode of action of such compounds, 21
crystal structures of a “gyraseCORE” fusion truncate of Staphyloccocus aureus DNA gyrase complexed with
DNA and diverse inhibitors have been published, as well as 4 structures lacking inhibitors. These structures
have the DNA in various cleavage states and appear to track trajectories along the catalytic paths of the DNA
cleavage/religation steps. The various conformations sampled by these multiple “gyraseCORE” structures
show rigid body movements of the catalytic GyrA WHD and GyrB TOPRIM domains across the dimer
interface. Conformational changes common to all compound-bound structures suggest common mechanisms
for DNA cleavage-stabilizing compounds. The structures suggest that S. aureus gyrase uses a single moving-
metal ion for cleavage and that the central four base pairs need to be stretched between the two catalytic sites,
in order for a scissile phosphate to attract a metal ion to the A-site to catalyze cleavage, after which it is
“stored” in another coordination configuration (B-site) in the vicinity. We present a simplified model for the
catalytic cycle in which capture of the transported DNA segment causes conformational changes in the
ATPase domain that push the DNA gate open, resulting in stretching and cleaving the gate-DNA in two steps.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Mechanism and Structure of Type IIA
DNA Topoisomerases
Topoisomerases are essential and ubiquitous
enzymes that regulate DNA topology by making
temporary single- (type I) or double-strand DNA
breaks (type II) [1,2]. The DNA double helix needs to
be unwound for processes such as DNA replication
or transcription to take place, giving rise to the
accumulation of positive supercoils ahead of tran-
scription bubbles and replication forks, and negative
supercoils or pre-catenanes behind. Topoisome-
rases relax supercoiled DNA and decatenate DNA
to allow DNA transcription and replication to take
place and are essential for genome stability [3–5].thors. Published by Elsevier Ltd. This
.org/licenses/by-nc-nd/4.0/).While the creation of temporary double-strand
breaks is necessary for the function of type II
topoisomerases, it is potentially hazardous for the
cell. Compounds that stabilize these normally
transient breaks are effective therapeutics used
both in cancer chemotherapy (e.g., etoposide) [6]
and as anti-bacterials (e.g., fluoroquinolones) [7,8].
Fluoroquinolones continue to represent a significant
class of weapons in the physician's armory against
pathogenic bacterial infections, with delafloxacin
approved for use by the Food and Drug Administra-
tion in 2017 [9]. Crystal structures of many drug
complexes show compounds bound in the DNA at
the cleavage site physically blocking religation, in an
apparently simple steric manner [10–14]. However,is an open access article under the CC BY-NC-ND license
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Fig. 1. Schematic of type IIA topoisomerases. (A)
Simplified schematic of the action of type IIA topoisome-
rases, such as yeast topoisomerase II (topo II), DNA
gyrase and topoisomerase IV. A segment of DNA (T-DNA)
is transported by capture through the ATPase domains
interface and passes through a transient double-strand
break established in the G-DNA (forming a DNA “gate”
interface with the WHD domain). The DNA then exits the
enzyme through the exit gate (EX). (B) Eukaryotic topo IIs
are homodimers, and many key structures have been
determined with a “core’ region (419–1180) encompassing
the TOPRIM domain (TOP), the Greek key fold, the
winged-helix domain (WHD), the Tower (TOW) and the
exit gate (EX). (C) Fusing the C-terminal region of S.
aureus GyrB (residue 409 to 644) to the N-terminal region
of GyrA (residue 2 to 491) gives an “equivalent” construct.
The Greek key can be deleted from this core construct in
S. aureus gyrase.
3428 DNA Topoisomerase Inhibitorscompounds such as the novel bacterial topoisomer-
ase inhibitors (NBTIs; GSK299423) [15] and the
thiophenes [16] bind away from the cleavage sites
and have allosteric mechanisms for the stabilization
of cleavage complexes. This points to the idea that
different compounds can stabilize different confor-
mations that the enzyme uses during the DNA
cleavage and religation steps of its catalytic cycle.
Two novel compounds in late-stage clinical devel-
opment [17,18], the NBTI gepotidacin and zolifloda-
cin (which like fluoroquinolones binds in the cleaved
DNA), are active against common fluoroquinolone-
resistant bacterial strains and, presumably,
fluoroquinolone-resistant forms of DNA gyrase
[17,19].
Type II DNA topoisomerases are divided into sub-
types, IIA and IIB [1,5], based on structural and
evolutionary considerations. Type IIA is found in
bacteria and eukaryotes, whereas IIB was discov-
ered in archaea and more recently in plants and
plasmodial parasites. Most bacteria have two type
IIA topoisomerases, DNA gyrase and topoisomer-
ase IV. DNA gyrase consists of two copies of GyrA
and two copies of GyrB and functions as an A2B2
heterotetramer (Fig. 1). Topoisomerase IV has two
homologous subunits, ParC and ParE, and also
functions as a heterotetramer. DNA gyrase can
uniquely introduce negative supercoils into DNA,
while topoisomerase IV performs strand passage
with two different double-stranded DNA segments
and has both decatenation and relaxation activity.
Eukaryotic type IIA topoisomerases are encoded as
a single protein, with regions equivalent to GyrB and
GyrA at the N- and C-terminus of a single subunit
(Fig. 1). Residues at the DNA cleavage catalytic
center are conserved between the eukaryotic and
prokaryotic type IIA topoisomerases.
Type IIA topoisomerases are able to transport a
segment of DNA across a series of interfaces that
form about the C2 symmetry axis (also called the
dyad axis) (Fig. 1A). The first interface is formed by
the two ATPase domains. ATP binding results in
dimerization and the trapping of the transported DNA
segment (T-DNA). The second interface is the so-
called DNA gate, where the gate-DNA (G-DNA) is
transiently cleaved, and residues involved in pro-
tein–protein interactions at this second interface
come primarily from the winged-helix domain (WHD)
as well as from the TOPRIM and Tower domains.
Once the T-DNA has passed through the G-DNA
(Fig. 1), it can then exit the enzyme through the “exit
gate” (EX). The C-terminal domain is less conserved
and is involved in substrate preference in topo IV [20]
and positive DNA loop wrapping by DNA gyrase.
DNA cleavage is achieved using a tyrosine residue
from the WHD (Tyr123 from the GyrA subunit in
Staphyloccocus aureus DNA gyrase), which forms a
phosphotyrosine bond with the cleaved DNA. A
catalytic metal ion (usually Mg2+) is required forcleavage and religation. Residues from the TOPRIM
domain are involved in coordinating the catalytic
metal. For DNA cleavage and religation to take
place, the catalytic tyrosine and the scissile phos-
phate need to be correctly positioned with respect to
the metal-binding TOPRIM domain. Type IIA topoi-
somerases have two active cleavage catalytic
pockets making a 4-base-pair staggered break in
the DNA. However, the catalytic metal ion has only
been observed when phosphates from the DNA are
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3429DNA Topoisomerase Inhibitorsclose enough to coordinate the metal directly or
indirectly via a water. The consensus is that a metal
ion must move to [15,21] or be present [22] at a
position contacting the scissile phosphate for DNA
cleavage to take place.
This article focuses on 25 crystal structures of S.
aureus DNA gyrase, all except 2 are complexes with
DNA, that have been deposited with the PDB (Tables 1
and 2). Several of these crystal structures have static
disorder around the twofold axis of the complex. Such
static disorder occurs when two (or more) stable
configurations are observed in the crystal, which results
in a density average, and are modeled by lowering the
occupancy of the alternative conformation. These
occupancy values reflect the frequency of the respec-
tive configurations in the crystal (see Ref. [23] pp. 373–
374 and Supplementary Methods). Taking this into
account, derived single biologically relevant complexes
are made available online (“Research” tab at https://
www.cardiff.ac.uk/people/view/1141625-bax-ben and
see Table S1). To facilitate comparison of these
structures, we adopt a standard BA-x numbering (for
GyrB-GyrA-extended; see SupplementaryMethods for
details). In this S. aureus DNA gyrase BA-x numbering
system, the catalytic metal is always called B5081 (or
D5081), and inhibitors have CHAIN ID I and are
numbered according to which pocket(s) they sit in (see
below). For example, in the 1.98-Å crystal structure of
GSK945237with a 20-bpduplex, both theDNAand the
compound have static disorder around the non-
crystallographic axis of the complex; coordinates
available are 5iwi-BA-x.pdb (crystallographic, with
standard nomenclature) and 5iwi-c1a.pdb and 5iwi-
c1b.pdb (“biological” single complexes derived from the
crystallographic coordinates in which a single DNAand
compound binding mode are present) (Table S1). We
also make available coordinates for a re-refined yeast
structure which sits on a crystallographic twofold axis
and is complicated by static disorder, RR-3L4K,
together with the originally deposited 3L4K structure
(Supplementary methods, Table S4s and S3 for the
refinement statistic). We also provide the DNA se-
quence and cleavage status for published gyraseCORE
model in Table S2.Apo and Binary DNA-Complexes of the
S. aureus GyraseCORE
As described previously [15,24], fusion truncates of
the C-terminal region of GyrB (409–644) with the N-
terminal region of GyrA (2–491) have been used in
determining 25 published structures of the S. aureus
gyraseCORE region. This construct is equivalent to the
eukaryotic topo II “core” used to solve key structures of
the eukaryotic enzymes (Fig. 1) [14,25,26]. The first
structures determined for S. aureus DNA gyraseCORE
were two apo structures (2XCO and 2XCQ) [15] (a
rendering of 2XCQ is shown in Fig. 2A). These initial
Table 2. Twenty-one crystal structures of the S. aureus DNA gyrase GyrBA fusion truncate with inhibitors
Active site 1 Active site 2
No. PDB
code +
res.
Inhibitor Inhibitor pockets occupied Metal B5081
site
occupancies
WHD
Tyr
C123
DNA DNA
cleavage
status
Metal D5081
site
occupancies
WHD
Tyr
A123
1 1′ 2D 2A 3 3′ A B A B
1 5iwi
1.98
‘945237 – – X X – – 0.55 0.45 Phe 20–12-823
20-23cmp
Singly nicked 0.45 0.55 Phe
2 2xcs
2.1 Å
‘299423 – – X X – – 1.0 – Phe 20–20
20–20
Not cleaved 1.0 – Phe
3 6qtk
2.31 Å
gepo′ – – X X – – 0.7 0.3 Phe 20–12-p8
20–12-p8
Doubly nicked 1.0 – Phe
4 6qtp
2.37 Å
gepo′ – – X X – – – 0.4 Tyr 20-444 T
20-444 T
Not cleaved 0.25 – Tyr
5 5iwm 2.5 ‘945237 – – X X – – 1.0 – Phe 20–21
20-21cmp
Not cleaved 1.0 – Phe
6 4bul
2.6 Å
‘966587 – – X X – – 1.0 – Phe 20–23
20-23cmp
Not cleaved 1.0 – Phe
7 5bs3
2.65 Å
cmpd 7 – – X X – – 1.0 – Phe 20–20
20–20
Not cleaved 1.0 – Phe
8 4plb
2.69 Å
AM8191 – – X X – – 1.0 – Phe 20–20
20–20
Not cleaved 1.0 – Phe
9 2 x c r a
3.5 Å
‘299423 – – X X – – – – Phe 20–20
20–20
Not cleaved – – Phe
10 5npp 2.22 ‘945237 + Thio2 – – X X X X – 1.0 Tyr 20-12p-8
20-12p-8
Doubly nicked – 1.0 Tyr
11 5npk 1.98 Thio1 – – – – X X – 1.0 Phe 20-12p-8
20-12p-8
Doubly nicked – 1.0 Phe
12 6qx1 2.65 Benzois′3 – – – – X X – 1.0 Tyr 20-12p-8
20-12p-8
Doubly nicked – 1.0 Tyr
13 6qx2 3.4 Benzois′3 – – – – X X – – Tyr 20-447 T
20-447 T
Mixed – – Tyr
14 5cdp 2.45 Etop. X – – – – – – 1.0 Phe 20-12p-8
20-12p-8
Doubly nicked 0.6 0.4 Phe
15 5cdm 2.5 QPT-1 X X – – – – – 1.0 TyrP 20-447 T
20-447 T
D o u b l y
cleaved
– 1.0 TyrP
16 5cdn 2.8 Etop. X X – – – – – 1.0 TyrP 20–447
20–447
D o u b l y
cleaved
– 1.0 TyrP
17 5cdq 2.95 Moxi. X X – – – – – 1.0 TyrP 20-448 T
20-448 T
D o u b l y
cleaved
– 1.0 TyrP
18 6fqm 3.06 IPY-t1 X X – – – – – 1.0 TyrP 20-448 T-U
20-448 T-U
D o u b l y
cleaved
– 1.0 TyrP
19 6fqvs3.11 IPY-t3 X X – – – – – 1.0 TyrP 20-448 T-U
20-448 T-U
D o u b l y
cleaved
– 1.0 TyrP
20 5cdo 3.15 QPT-1 X X – – – – – 1.0 TyrP 20-447 T
20-447 T
D o u b l y
cleaved
– 1.0 TyrP
21 2xct 3.35 Cipro. X X – – – – – 1.0 Phe 20–12-823
20-1223c-823c
Doubly nicked – 1.0 Phe
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Fig. 2. Comparison of an apo and a
DNA complex of S. aureus gyrase. (A)
Two orthogonal views of a 2.98-Å
crystal structure (PDB code 2XCQ;
[15]) of the S. aureus gyraseCORE
fusion truncate (see Fig. 1). One
subunit is in red (GyrB) and blue
(GyrA), and the other in black (GyrB)
and gray (GyrA). Note that the walls of
the G-DNA binding canyon are
formed by the TOPRIM (TOP) and
tower (TOW) domains, while the
winged helical domains (WHD) form
the floor. (B) Two equivalent views of
a 2.6-Å crystal structure (PDB code
6FQV; [11]) of a binary complex of the
gyraseCORE-GKD (Greek key deletion)
with DNA. Note that the GK domain
(544–579) has been deleted from
GyrB, and replaced with two residues,
Thr and Gly (see text). Note also that
on binding DNA, the C-terminal region
of the TOPRIM domain becomes
ordered (B509–B638) and (A10–
A26) and interacts with the DNA (in
green).
3431DNA Topoisomerase Inhibitorstwo structures were determined bymolecular replace-
ment using the Escherichia coli A59 structure (1AB4)
as a search molecule [27]. Both structures are at
medium-low (which we define as 2.01–3.0 Å) to low
(N3.0 Å) resolution and have a single gyraseCORE
subunit in the asymmetric unit, the dimer being
generated by a crystallographic twofold axis (our
definitions of resolution reflect the difficulty in
locating waters and having experimental data that
clearly define metal coordination geometry in low- or
medium-low- resolution crystal structures). The apo
structures both contain a number of intrinsically
disordered regions, including three α-helices at one
end of the TOPRIM domain (Bα9, Bα10 and the N-
terminal region of Aα1) and a number of loops that
are ordered upon DNA binding (see below). Al-
though the apo S. aureus crystals were grown in theNotes to Table 2:
The TOPRIM-bound metal is named B5081 (or D5081) to indicate th
positions (see Fig. 6 for details). Active sites are formed across the dim
approaching the B TOPRIM domain, and the tyrosine from the BA sub
“cleaved” means a phosphotyrosine bond is established, whereas “nic
a Greek key present.presence of 150 mM calcium acetate (2XCO), or
85 mM magnesium formate (2XCQ), no catalytic
metal was observed in either structure at the metal-
binding site on the TOPRIM domain. In S. aureus
gyrase, metals have only been observed at the
metal-binding site on the TOPRIM domain when
they interact either directly with the scissile phos-
phate from the DNA (the so-called “A-site” for metal
binding), or when they interact with an adjacent
phosphate from the backbone via a water molecule
(the “B-site,” see below for the precise depiction of
the metal-binding sites). This suggests that DNA
binding is required to form binding sites for the
catalytic metals, which involve coordinating groups
from both the TOPRIM domain and the DNA.
However, some DNA-containing structures do not
have metals (Tables 1 and 2).at it is coordinated by Asp 508 from GyrB, in both the A and B
er interface with the catalytic tyrosine from the DC subunit (C123)
unit (A123) approaching the D subunit TOPRIM domain. Note that
ked” mean the 5′ phosphate is untethered.
90°
(c)
(a)
TOP
-1 helix
WHD
1
1’
2
3’
(b)
(d)
(f)(e)
3 
3 
3’ 
2
1’
1
Asp83
Asp83
thiophene 2
moxiﬂoxacin
GSK945237 
Fig. 3. Inhibitors (I) can stabilize the cleaved state through binding at different positions. (A) View of the un-cleaved
binary complex equivalent to Fig. 2c. (B) Closer view of the binary complex (6FQV) showing the proximity of the two Asp83
residues at the WHDs interface. (C) Global view of compound binding sites on the S. aureus gyraseCORE illustrated by
moxifloxacin (in sites 1 and 1′), GSK299423 (in site 2) and thiophene 2 (in sites 3 and 3″). The structure represented is a
composite between a thiophene 2 and GSK945237 bound structure (PDB code: 5NPP) and a moxifloxacin-bound
structure (PDB code: 5CDQ). (D) Closer view of the moxifloxacin structure (5CDQ) showing moxifloxacin (I1 and I201),
Mn2+ (yellow sphere) and the separation of the Asp83 residues. (E) Alternative view of the composite representation
shown in panel C. (F) Closer view of the NBTIs/thiophene structure (5NPP) showing GSK945237 (2), and thiophene 2 (3
and 3′), Mn2+ (yellow sphere) and the separation of the two Asp83 residues.
3432 DNA Topoisomerase InhibitorsA 2.6-Å binary complex between DNA and
gyraseCORE structure (6FQV), [11] (Fig. 2) does
not have any compounds bound and the DNA is
intact, despite the enzyme being functional for
cleavage (Table 1). The DNA sits in a groove
formed by the TOPRIM domain on one side andGyrA on the other side and below (Fig. 2B). Despite
being obtained from crystals grown in the presence
of Mn2+ ions, which can substitute Mg2+ in
catalyzing phosphotransfer, no metal is observed
at the catalytic site (the crystals for 6FQV were
grown in conditions essentially the same as used
DC
BA GyrB
DC GyrB
BA GyrA
Glu B435
Mn2+
B5081
Mn2+
D5081
(b) DNA
Glu 
D435
Asp
D508
Phe
A123
DC GyrA
TyrP
C123
Asp
B508
BA GyrB
DC GyrB
BA GyrAAspB510
Mn2+
B5081
Mn2+
D5081
(a) DNA
Asp
D508TyrP
A123
Asp
D510
QPT1
GSK299423 
Phe
C123
Fig. 4. Comparison of cleaved and uncleaved DNA complexes. (A) The 2.5-Å structure of QPT1 (I1 and I201 in
coordinates avalailable in our website, see text) with cleaved DNA (PDB code 5CDM; [10]). One subunit has carbons in
magenta (GyrB) and slate-blue (GyrA), and the other in black (GyrB) and gray (GyrA); carbons in DNA are green. Oxygens
are red; nitrogen, blue; and sulfur and phosphorus, orange. Residues contacting the catalytic metal and the catalytic
tyrosine (TyrP A123 and TyrP C123) are shown as fatter sticks, and most residues are in thinner line representation.
Carbons in inhibitors (I1 and I201) are yellow. The phosphorus in the scissile phosphate is also highlighted in yellow and
arrowed (black arrows). Dotted lines between the 3’-OHs (red arrows) and phosphorus atoms illustrate that after cleavage
in this complex, these atoms are some 6.5 Å apart. (B) The 2.1-Å structure of GSK299423 (I 2) with uncleaved DNA (PDB
code 2XCS; [15]). The black arrows point at the phosphorous atom, and the red arrows point at the 3′-oxygen of the bond to
be cleaved. The catalytic tyrosine has been mutated to a phenylalanine (Phe A123 and Phe C123).
3433DNA Topoisomerase Inhibitorsfor other structures, in which Mn2+ ions were
observed at the TOPRIM domain metal-binding
sites; see below and Tables 1 and 2). This is
presumably due to the phosphates from the DNA
backbone being too far from the TOPRIM aspartate
residues involved in coordination (notably Asp508)
for normal metal binding to occur. Both Mg2+ and
Mn2+ favor octahedral coordination [28] with
favored distances of around 2–2.3 Å, and the
distance between the scissile phosphate and
Asp508 is around 8 Å, precluding the formation of
a coordination site. Therefore, DNA binding isessential but not sufficient for the formation of a
metal-coordination site. Comparing with the apo
structures (Fig. 2), DNA binding results in the
ordering of the three α-helices from the TOPRIM
domain (Bα9, Bα10 and the N-terminal region of
Aα1). The Greek key domain (GK) is deleted in this
complex, and this has been important in obtaining
higher-resolution DNA-bound gyraseCORE struc-
tures (currently the only S. aureus gyrase DNA
complex with the GK domain present is the 3.5-Å
complex with GSK299423; 2XCR, the equivalent
complex with the GK domain deleted, is at 2.1 Å,
3434 DNA Topoisomerase Inhibitors2XCS; Table 2). In the S. aureus gyraseCORE GK
deletion, residues 544–579 from GyrB are deleted
and replaced with a threonine (T) and glycine (G),
giving a sequence 540-AQPP-TG-YKGLGE-585.
We underline the YKGLG motif as it might have
some role in the control of DNA cleavage (see
below for discussion of our model).Broad open pocket - can 
accommodate various 
substituents at C7 position 
on quinolones 
The barbituric acid moiety of 
QPT-1 can change tautomers to 
maintain favourable interactions 
with GyrB as the DNA-enzyme 
GyrB
DNA
GyrA
Ser A84 
Glu
A88 
1
2 3
4
5
67
8
GyrB
GyrA
Ser A84 
Glu
A88 
Water-metal ion bridge allows 
contact to be maintained as the 
DNA moves the enzyme around. 
Major part of 
quinolone 
'intercalated' 
in DNA at 
cleavage site
(a) Moxifloxacin
(b) QPT-1 cf zoliflodacin
QPT-1 (bold), the progenitor 
of zoliflodacin (faint), has an 
NO2 group at the
'top' (as shown). 
Zoliflodacin has 
been modified 
cf QPT-1 at the
'top' but the
'lower' part 
is the same.
DNACompounds Binding at Three Different
Sites Can Stabilize DNA-Cleavage
Complexes
Structural studies on S. aureus DNA gyrase have
identified three different sites (comprising pockets 1,
2A, 2D and 3) at or near the DNA gate where
compounds (Supplementary Fig. 1 shows the chem-
ical structures of compounds) can bind and stabilize
DNA-cleavage complexes (Fig. 3); two of these
pockets are largely within the DNA, and two in the
protein. Site 1 (1′ for the symmetry mate) is in the
cleaved DNA at the DNA-cleavage site. Compounds
binding in this pocket often seem to physically block
religation in a simple steric manner (Figs. 3 and 4A).
Such compounds often bind at both cleavage sites
(four base-pairs apart) and can stabilize double-strand
cleaved complexes (compounds haveChain ID I1 and
I201 for the symmetry mate in the models). Pockets
2D and 2A constitute site 2 and can be occupied by
the NBTIs, which sit on the twofold axis of DNA
complexes. The left-hand side (LHS) of an NBTI
compound, like GSK299423, occupies a pocket
between the central base-pairs of the DNA (pocket
2D), while the right-hand side (RHS) occupies a
pocket between the two GyrA subunits (pocket 2A) at
the interface between the 2WHDs. The LHSandRHS
are linked by a central unit (Fig. 4B). Compounds in
these pockets haveChain ID I2 in themodels. Site 3 is
a hinge pocket, between the GyrA and GyrB subunits
[16]. Thiophenes that bind in the hinge pocket (Fig. 3)
can stabilize both single- and double-stranded cleav-
age complexes [16]. Compounds in pocket 3 sit at the
interface between GyrA and the TOPRIM domain on
the outside of the enzyme. They do not contact the
DNA (Fig. 3). Compounds in pocket 3 have Chain ID
I3 and I203 in our structures (“Research” tab at https://
www.cardiff.ac.uk/people/view/1141625-bax-ben
and see Table S1).complex wobbles. 
Fig. 5. Simplified schematics of binding modes of
moxifloxacin and QPT-1 in site 1. Simplified schematic
binding modes derived from S. aureus gyraseCORE crystal
structures with DNA [16] are shown for the following: (A)
moxifloxacin and (B) QPT-1. In panel B, zoliflodacin, a
derivative of QPT-1, is shown faintly (see Supplementary
Fig. 1 for chemical structures). Compounds binding in
pocket 1 (largely within the DNA—green rectangle) can
extend out of the DNA into a broad open pocket on GyrB.Site 1
Compounds binding in site 1 tend to be slightly
wedge-shaped compounds that intercalate in the
DNA at each cleavage site contacting bases from
the DNA. Compounds sitting in this pocket can make
contacts with the GyrA WHD and/or the GyrB
TOPRIM domain. We have obtained crystal struc-
tures with this pocket occupied by fluoroquinolones(FQ), the quinoline pyrimidinetrione (QPT-1), etopo-
side [10] and imidazopyrazinones (IPYs) [11] (Fig. 3
and Table 2). Anti-bacterial quinazolinediones (QZ)
also occupy this pocket; a structure with a QZ bound
to the same pocket has also been obtained [21]. The
standard fluoroquinolone-binding mode involves
interactions with the GyrA subunit via the now well-
characterized water–metal ion bridge (Fig. 5)
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Fig. 6. A-configuration and B-configuration metal coordination. (A) Left panel: The 2.1-Å structure of GSK299423 (PDB
code: 2XCS) has a Mn2+ ion at the A (or 3′) site. For clarity, only the DNA, compound, catalytic tyrosine (mutated to Phe),
metal and coordinating residues and waters (small red spheres) are shown. View is similar to Fig. 4B. The dotted lines
show approximate positions of Asp 508 and Mn2+ ion for B-configuration metal. Right panel: Density around the modeled
Mn2+ in 2XCS (blue cage, contoured at 8.4 rmsd). The coordinating oxygens were omitted, and the difference map (light
green cage, contoured at 5.4 rmsd) is shown around the modeled coordinating oxygen. (B) Left panel: The 2.5-Å structure
of QPT-1 (PDB code: 5CDM) has a Mn2+ ion in the B-configuration (similar view to Fig. 4A). The DNA has been cleaved by
the catalytic tyrosine. Carbon atoms in DNA covalently attached to the catalytic tyrosines are colored as in tyrosine A123
(slate-blue) or C123 (gray). The position of an A-configuration metal is shown (broken circle) as in panel A, left panel. Right
panel: Density around the modeled B-configuration Mn2+ for 5NPP (the highest-resolution B-configuration metal structure)
is shown as in panel A, right panel (contoured at 5.1 rmsd). The omit map for coordinating oxygen is shown as above in a
lighter-green cage (contoured at 4.1 rmsd).
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water–metal ion bridge may be important. Blower et
al. [30] report that, for Mycobacterium tuberculosis
gyrase complexes with DNA and fluoroquinolones,
complex stability correlates with antimicrobial activity.
Structure-guided drug design has recently produced
some more potent fluoroquinolones [32–34]. Fluor-
oquinolones modified at the N1 position, which are
gyrase inhibitors but do not promote DNA cleavage,
have also been reported [35]. The water–metal ion
bridge is important for the stability of the complex, and
residues involved in coordinating the metal are
frequently mutated in bacterial strains that are
resistant to the FQs [36]. This and safety concerns
with fluoroquinolones (https://www.ema.europa.eu/en /med ic ines /human/ re fe r ra l s /qu ino lone-
fluoroquinolone-containing-medicinal-products) are
spurs to investigate the antibacterial therapeutic
potential of other chemotypes binding in this pocket.
The QZs are such compounds and rely on other
interactions for the stability of the complex. The IPYs
are a new class of bacterial type IIA topoisomerase
inhibitor that bind at site 1 that do not form a water–
metal-ion bridge but do establish contact with the
serine involved in its formation, leading to some cross-
resistance [11,37]. They also establish contact with
the arginine located just before the catalytic tyrosine in
the primary sequence [11]. Interestingly, this arginine
is essential for cleavage and therefore cannot be
acquired as a resistance mutation by pathogens.
3436 DNA Topoisomerase InhibitorsCurrently, the most advanced novel chemotype
site 1 binder is zoliflodacin, a derivative of QPT-1
[18]. Structural studies suggest that the ability of the
barbituric acid moiety on QPT-1 to adopt different
tautomers may be important in allowing compounds
to remain bound as pocket 1 changes shape [10].
The barbituric acid does not definitely adopt a
pyrimidinetrione tautomerwhen inhibiting the enzyme;
therefore, we suggest the term quinoline barbituric
acids (QBAs) rather than quinolinepyrimidinetriones
(QPTs) for this class of inhibitor [10]. However, we
stick to the accepted terminology throughout this
review to avoid confusion. The amino acid residues
that QPT-1 interacts with on GyrB are conserved in
human type IIA topoisomerases. Therefore, the
specificity of QPT-1 for bacterial topoisomerases is
difficult to explain but may be due to small differences
in the size and shape of pocket 1 in the bacterial and
human enzymes, or to differences in the energetics of
the DNA gate (see below). Having a totally different
scaffold in the same pocket as fluoroquinolones offers
many opportunities for “scaffold hopping” (Fig. 5), and it
will be exciting to see how theQPTclass of compounds
progress in phase III clinical trials and beyond.
Imidazopyrazinones are a new class of bacterial type
IIA topoisomerase inhibitor that bind in site 1 [11].
Interestingly, although one crystal structure (with two
complexes in the asymmetric unit) was observed to
have doubly cleaved DNA at both cleavage pockets
(IPY, 6FQM, Table 2), the other IPY crystal structure
contain both a doubly cleaved complex and a cleavage
complex with two compounds, but only one strand
cleaved (IPY-t3, 6FQS,Table 2;SupplementaryFig. 2).
In the complex with one strand cleaved and one strand
uncleaved, the compound has a different bindingmode
at the pocket with the uncleaved strand. This suggests
that transitioning to the cleaved state is accompanied
by a flipping of the compound. It is known that
fluoroquinolones can bind the enzyme without cleav-
age occurring [38]. It would therefore be interesting to
try to determine a crystal structure of a fluoroquinolone
in complex with uncleaved DNA and the YtoF mutant,
to see if a similar flip in binding mode occurs on
cleavage with fluoroquinolones to that we have
observed with IPY-t3 (Supplementary Fig. 6).
Etoposide is an anti-cancer drug that also has
antibacterial activity [10]. Crystal structures show
that the way etoposide binds to human topoisomer-
ase II [14] and S. aureus gyrase [10] is very similar.
The ability of etoposide to stabilize single-stranded
DNA cleavage (as well as double-stranded DNA
cleavage) at a range of concentrations with both
bacterial [10] and human [39] type IIA topoisome-
rases is interesting and constitutes an exception
among the pocket 1 binders, which generally
stabilize double-strand cleavage. It is not yet clear,
when one etoposide is bound, if the DNA is cleaved
where the etoposide is bound, or if it is cleaved four
base-pairs away as some data suggest [40].Site 2
Novel (or non-fluoroquinolone) bacterial topoisom-
erase inhibitors (NBTIs) were discovered in SmithKline
Beecham in the 1990s and developed at GSK to
produce gepotidacin, an NBTI that is currently going
throughphase II clinical trials [19]. TheNBTIswere also
developed simultaneously by Rhone-Poulenc Rorer
(now part of Sanofi); see Ref. [41] for a historical
perspective on the development of these compounds.
The nameNBTI [15] has caused some confusion in the
literature. In this review, we apply the name NBTIs to
the compounds that sit in the two pockets (forming site
2, see below) on the twofold symmetry axis. This is in
accordance with accepted terminology. However, we
suggest that a better name for this class of compounds
might be taps-NBTIs (for twofold axis pockets binding
NBTIs) to clearly distinguish them from the many other
novel (non-fluoroquinolone) bacterial topoisomerase
inhibitors that continue to emerge.
NBTIs do not have a single chemical scaffold;
however, they have some features in common that
that allow them to bind on the twofold axis of the
complex as shown in structures solved at GSK
[15,16,42,43] and by others [44,45], namely, a planar
LHS that intercalates on the twofold axis of the complex
in a pocket in the DNA midway between the two
cleavage sites (pocket 2D) and an RHS that sits in a
pocket between the two GyrA subunits on the twofold
(pocket 2A), and a central linker that usually has a basic
nitrogen adjacent to Asp83 (in S. aureus DNA gyrase;
Fig. 4). Although pocket 2A (the GyrA pocket) is
conserved in bacterial gyrases and topo IVs, it is not
conserved in human topo IIs, accounting for the
specificity of NBTIs [15].
The initial S. aureus gyraseCORE crystallization
system was developed in GSK to support the
development of NBTIs. The optimization of the DNA
sequence and identification of a more stable complex
with Mn2+ (cf Mg2+ or Ca2+) and the catalytic Y123F
mutant were critical in producing initially, a 3.5-Å
crystal structure with GSK299423, then with the
deletion of the GK domain, a 2.1-Å structure was
generated [15]. This structure produceda clear viewof
the A (or 3′) metal coordination at the DNA cleavage
sites, including the waters coordinating the catalytic
metal ion. However, because GSK299423 sits on the
twofold axis, the electron density for the compound is
averaged around the non-crystallographic twofold
axis of the complex and the water structure around
the compound is not so clear (Supplementary Fig. 8).
A 2-year campaign in GSK to try and produce NBTI
crystal structures in this P61 space group with the
compounds in a single orientation, trying to exploit the
fact that the ends of the DNA pack differently in this
space group, produced structures with asymmetric
DNAs disordered around the non-crystallographic
twofold symmetry axis [42,43]. The highest resolution
(1.98-Å) structure, with GSK945237, had an artificial
3437DNA Topoisomerase Inhibitorsnick in one strand and the electron density maps for
the active sites were clear, although there was static
disorder around the non-crystallographic twofold
symmetry axis. The conclusion from this 1.98-Å
GSK945237 structure [43] was that the metal coordi-
nation geometry for the A (3′) and B (Y) metal binding
sites are incompatible with two metals being bound at
the same time.
Site 3
This site is formed by a pocket situated between the
GyrA and GyrB subunits (Fig. 3), and compounds
binding in this pocket do not contact the DNA.
However, they can stabilize both double- and single-
strandedDNA-cleavage complexes [16]. The “floor” of
the pocket is partly formed by the Aα1 helix (from
GyrA). This Aα1 helix is inserted into the TOPRIM
domain and bends at its C-terminal end (proximal to
pocket 3) when the apo and DNA-bound S. aureus
gyrasecore complexes are compared, hence arriving
at the name “hinge pocket.” However, sequence and
structural differences suggest that it does not do this in
eukaryotes. Although most S. aureus gyrasecore
complexes with DNA and compounds have the
GyrA and GyrB subunits within a covalently fused
gyrasecore subunit in the same orientation [10], the
2.6-Å binary complex (6FQV, Table 1) shows a
distinct movement between the TOPRIM domain
(which includes the N-terminal end of the Aα1 helix)
and the WHD (which includes the C-terminal end of
the Aα1 helix) within a covalently fused subunit
(compare Fig. 3A and C). Pocket 3 assumes a
different shape in crystal structures of gyrasecore
DNA-cleavage complexes compared to the binary
complex with uncleaved DNA [11,16]. Superposing
the 1.98-Å crystal structure of thiophene1with the 2.6-
Å binary structure shows clashes of the compound
with the protein in the binary structure conformation
(Supplementary Fig. 7). Therefore, we conclude that
compounds such as thiophene 1 inserting into the
pocket prevent DNA cleavage complexes from relax-
ing into the binary state.
The 1.98-Å complex with thiophene 1 is the
highest-resolution structure we have obtained con-
taining B-configuration metal geometry, which ap-
pears conserved between bacterial and human type
IIA topoisomerases. The highest-resolution structure
we have obtained with an A-site metal is the 2.1-Å
structure with GSK299423 (Table 2).The Role of S. aureus GyraseCORE
Crystallization System in Compound
Development
Although much of drug development is concerned
with optimizing the ADMET properties of com-pounds, target potency cannot be ignored. The
solving of structures showing compounds bound to
their target thus remains an essential part of pre-
clinical compound development, helping the chem-
istry effort in maintaining or improving specificity and
potency.
The S. aureus gyraseCORE crystallization system,
developed by GSK to support the development of
NBTIs, had relatively little impact on the chemical
development of gepotidacin, which is similar to
important progenitor compounds GSK966587 [42]
and GSK945237 [43], which were synthesized
before the first S. aureus gyraseCORE structure
with an NBTI was determined (see Supplementary
Fig. 1 for chemical structures). Although many
potent NBTIs with good antibacterial activity have
been reported, a major challenge remains hERG
toxicity [42,46], for which target-bound structure are
not particularly helpful.
The successful structure determination of the
first structure of a fluoroquinolone complex show-
ing the water–metal ion bridge in GSK, the 3.25-Å
moxifloxacin complex with Acinetobacter bauman-
nii topo IV [13], used a DNA sequence identified by
Arnoldi and co-workers [47] (Table S2) and
followed the deposition of a quinazolinedione
structure in the PDB [21]. The identification of the
water–metal ion bridge was essential in illuminat-
ing target-based resistance to fluoroquinolones
and helped the development of new compounds
overcoming this resistance. Early attempts to use
the S. aureus gyraseCORE system for fluoroquin-
olone structure determinations at GSK were not
successful, tending to produce limited resolution
ambiguous data sets such as the 3.35-Å twinned
ciprofloxacin structure, which we have now re-
refined and re-deposited with the PDB (2XCT; see
Supplementary Materials). Therefore, the determi-
nation of the first medium-high-resolution structure
of a fluoroquinolone complex [30] was an impres-
sive feat. Fluoroquinolone crystals do not tend to
diffract to very high resolution, and Blower et al.
[30] reported that with the M. tuberculosis gyrase
crystals they used, “the diffraction quality varied
greatly not only between crystals but also between
different regions of a single crystal.”
The deletion of the GK domain in the S. aureus
gyraseCORE produced a dramatic improvement in
resolution in complexes with the NBTI GSK299423,
from 3.5 to 2.1 Å (Table 2), as well as a clear view of
an A active-site metal. Attempts to reproduce this GK
deletion strategy in about 10 Gram-negative gyrases
and topo IVs were not successful.
The initial 1.98-Å thiophene hinge binder com-
plex facilitated the building of higher activity into the
initial compounds through an added methyl group,
filling a cavity in the hinge pocket [16]. This
illustrates the usefulness of the gyraseCORE in
3438 DNA Topoisomerase Inhibitorsbuilding potency, especially when higher resolution
can be achieved. More recently, structure-guided
drug design has produced a second class of hinge
binder compounds [48].
Finally, the use of the S. aureus gyraseCORE
crystal system to investigate other antibacterial
gyrase “poisons” has produced some interesting
structures [10,11,16]. Consideration of these struc-
tures has allowed us to develop two different single-
moving-metal mechanisms for DNA cleavage by S.
aureus gyrase (one of these is presented in Figs. 7
and 8 and below, and an alternative model is
presented in the Supplementary discussion and
Supplementary Figs. 9 and 10). It is difficult to
prove mechanisms, but it is hoped that by consid-
ering different possibilities, experiments can be
devised that can distinguish between them. The
two single-moving-metal mechanisms we present
have many aspects in common (below and in
Supplementary discussions) but are different.Why Different Compounds Stabilize
Different Amounts of Single- and
Double-Strand Cleavage
We have mentioned that each class of compounds
presents a characteristic ratio of double- to single-
strand cleavage. The above considerations fail to
explain this. It is important to note that each strand of
DNA is involved in the formation of its own catalytic
cleavage pocket through involvement (directly or via
a water molecule) in the coordination of the catalytic
metal.
Interestingly, although compounds binding in
pocket 3 stabilize both double- and single-stranded
DNA-cleavage complexes, they do so without
changing the preference for cleavage sites seen (at
a much lower level) in the absence of compounds
[16]. This contrasts with fluoroquinolones, which do
change cleavage site preferences, presumably
through their interaction with DNA [16]. This sug-
gests that interaction with the DNA near the
cleavage site can influence cleavage.
We have mentioned that two binary complexes
have been solved with S. aureus gyrase (6FQV and
5CDR). The relative positions of the domains within
a gyraseCORE subunit in 6FQV are different from
those in any other S. aureus gyrase core complex
with DNA. 6FQV has domains in positions interme-
diate between the apo structures and the other S.
aureus complexes with DNA and traps an
“uncleaved” conformation (see below). In 5CDR,
introducing artificial “nicks” in the DNA at both
cleavage sites, by annealing a 12mer with a
phosphate at the 5´ end with an 8mer, gives a 20-
bp duplex which crystallizes well (20-12p-8; Tables 1
and 2) [24]. However, in the binary complex with thisartificially doubly nicked DNA (5CDR), the central
four base pairs (where the four base-pair overhangs
should anneal) of the DNA are largely disordered.
Interestingly, a similar observation is made with the
1.98-Å structure, which has a compound bound in
the allosteric hinge pocket but no compound in the
DNA (5NPK; Table 2) [16]. This disorder has been
similarly observed in a human topo II structure [25].
On the other hand, crystal structures obtained with
the same doubly nicked DNA and compounds bound
to the DNA show ordered central base pairs (e.g.,
the etoposide-bound structure [10]). This again
points toward the idea that compounds that interact
with DNA in the central region can influence its
structure and therefore its cleavage status. We
surmise that when the cleaved conformation is
adopted by the enzyme, the DNA has some flexibility
and can oscillate between single-, double-strand
cleaved and uncleaved, unless a compound(s) is
bound to the DNA and inhibits this flexibility, thereby
favoring single- or double-strand cleavage. In
biochemical assays, complexes stabilized by the
hinge binders are a mixture of uncleaved, single- and
double-strand cleaved [16]. When the full-length
enzyme is not bound by compounds, the addition of
ATP also results in a mixture of trappable single- and
double-strand cleavage [11,16]. This suggests that,
during the catalytic cycle, the enzyme naturally and
transiently can adopt cleaved conformations.
In that view, the symmetrical binding of FQs to
pocket 1 would favor double-strand cleavage by
favoring the formation of a catalytic cleavage pocket
on both sides. The NBTIs on the other hand stabilize
only single-strand cleavage, which is consistent with
them having an asymmetrical binding mode. In the
2.1-Å crystal structure of GSK299423 with S. aureus
gyrase and DNA (2XCS), the compound sits on the
twofold axis and is not C2 symmetric (see above).
Since such asymmetric compounds interact with
DNA, it is likely that they can asymmetrically
influence DNA conformation and thereby stabilize
only single-strand cleavage. However, the exact
conformation of DNA in this asymmetric complex is
difficult to ascertain due to the lack of crystal
structure with compound and DNA in a single
orientation. More specifically, it has not yet been
possible to correlate a compound orientation to a
DNA orientation.General Mechanistic and Energetic
Features of DNA Gyrase Poisoning
The ability of compounds to stabilize DNA gyrase-
DNA cleavage complexes is dubbed “poisoning” as it
converts an essential enzyme into a deleterious
lesion. These have, to date, been much more
successful in the clinic than the “catalytic” ATPase
inhibitors [50]. The mechanism described above for
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3439DNA Topoisomerase Inhibitorsthe allosteric hinge binders reflects general features of
the mechanism of poisoning by a variety of com-
pounds binding to a variety of pockets. Compound
binding to any of the pockets is generally associated
with a “sliding” of the WHDs along the DNA gate
interface. This is accompanied by a “tilting” of each
TOPRIM domain toward the DNA (Fig. 3A, C),
accompanying the C-terminal bending of the Aα1
helix described above. These motions were also
observed by Wendorff et al. [51] with an etoposide
complex with human topo II, suggesting that they are
conserved across type IIA topoisomerases. The DNA
itself is extended compared to the binary complex
and, as a result, the distance between the scissile
phosphate and the metal-coordinating residues is
reduced and allows the capture of a catalytic metal
(usually Mn2+ in S. aureus gyraseCORE structures).
Indeed, nearly all the compound-bound structures
have a single metal bound at the catalytic site,
whereas the binary uncleaved complex and the apo
structures do not. Thesemovements are small (b5 Å)
but relatively consistent across compound-bound
structures and represent a transition toward the
cleaved state, which is stabilized by compoundFig. 7. Dynamic model for the cleavage–religation cycle
catalyzed by a single metal ion. (1) Relative movement of
the GyrA subunit (see Fig. 3), extension of the DNA and
tilting of the TOPRIM domain create a coordination
environment for a single metal ion, the A-configuration,
involving Asp508 residue from the TOPRIM domain, water
molecules, and two oxygens from the scissile phosphate
(see inset). (2) Through its contacts with the scissile
phosphate, the metal catalyzes phosphotransfer to the
catalytic tyrosine. The phospho-tyrosine then moves away
after cleavage, disrupting the A-configuration, which favors
the transfer of the metal to the B-configuration (inset)
initially filled by a water molecule contacting the A-
configuration metal. (3) Opening of the DNA gate
obliterates the A-configuration but does not affect the B-
configuration, allowing the metal ion to be stored in the B-
configuration during strand passage. Keeping the catalytic
metal away from the phospho-tyrosine can prevent
detrimental hydrolysis of the bond during strand passage.
(4) Closure of the DNA gate brings the phospho-tyrosine
closer to the catalytic metal in the B-configuration. (5) We
hypothesize that phospho-tyrosine is being brought even
closer to the B-configuration coordination cage and can
disrupt a coordinating water molecule, resulting in metal
recapture by the phosphate and the catalysis of phospho-
transfer to the 3´-OH (which remains close to the B-
configuration during the cycle). This re-creates the A-
configuration and panel 6. Relaxation into the binary state
can then ensure irreversibility by disrupting the A-
configuration. We envision that controlling the motion of
the DNA and the position of the scissile phosphate allows
the enzyme to control cleavage and religation. This control
is presumably coupled to the ATP hydrolysis and
exchange cycle. Alternatively, a compound binding the
enzyme might also influence the position of the scissile
phosphate.
3440 DNA Topoisomerase Inhibitorsbinding. The sliding of the two WHDs opens up a
cavity (pocket 2A) intowhichGSK299423 can bind, as
evidenced by the separation of the two D83 residues
from the WHDs, which are close enough to establish
contact at the interface in the uncleaved binary
complex (Fig. 3B). Consistently, mutating D83 to anGyrA'
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3441DNA Topoisomerase InhibitorsThese domain movements are not simply a result
of DNA cleavage since they are observed in the
GSK299423-bound structure (2XCS) in which the
catalytic tyrosines are mutated to phenylalanines
and the DNA is therefore intact [15]. Moreover, data
suggest that a significant proportion of thiophene–
gyrase–DNA complexes do not have the DNA
cleaved [16]. Similarly a significant proportion of
gepotidicin complexes do not have the DNA cleaved
[52]. In the case of pocket 1, compounds intercalate
and we speculate that it favors the extension of the
DNA. Moreover, the transition to the cleaved state
favors the alignment of residues involved in contact-
ing the compound and the cavity between the two
bases. It is known that fluoroquinolones can bind the
enzyme without cleavage occurring [38], again
suggesting that the transition to a different confor-
mation precedes, and determines cleavage. It is
possible that the steric impediment to religation also
plays a role in the efficiency of cleavage for these
compounds. Indeed, they are usually more efficient
than the allosteric compounds (NBTIs and
thiophene).
We therefore suggest a model in which the
enzyme needs to undergo conformational changes
resulting in DNA extension and the formation of a
favorable coordination site for a single metal ion,
which can then catalyze the phosphotransfer reac-
tion to achieve DNA cleavage. The primary mode of
action of compounds is to stabilize this otherwise
unfavorable state (as low or no cleavage is observed
in their absence). The only structure of type II
topoisomerase with the DNA gate opened was
recently published [25]. In this structure (with
human topo II), the WHDs separate seemingly by a
sliding motion similar to the one we describe, only
more extensive. We therefore speculate that the
transition to the cleaved state would constitute a
“prelude” to the opening of the DNA gate by a
continuation of the sliding motion. However, no
bacterial type IIA topoisomerase structure with
DNA bound and the DNA gate opened has yet
been obtained.
This suggests that in order to cleave theDNA, gyrase
has to stretch the central four basepairs. This increases
the distance between the scissile phosphates and
reduces the stacking interactions between the central
bases. DNA is a very deformable molecule, but thisFig. 8. A simplified model for DNA cleavage by S. aureus
complex, based on binary structure (6FQV). No metal is bou
backbone (green). D83 and D83’ are close to each other at
segment has been captured (not shown) and the domains at
DNA. (C) A single metal (yellow sphere) is captured in the A-c
cut, the metal is in the B-configuration, the gate is pushed furthe
other side. (E) Both DNA strands are now cleaved. Metals a
through the DNA gate. (G) The above model is broadly consiste
the enzyme and S is the substrate DNA, which is either unc
cleaved (E-S11—E,F).stretching will have some energetic cost. It may also
explain the vulnerability of theDNA-gate to intercalating
compounds, which can also stretch the DNA. Accord-
ing to thismodel, the energy of compound bindingmust
compensate the energetic cost of transitioning to the
cleaved state. This energetic cost is presumably due to
the loosening of the protein interface in addition to the
stretching of the DNA. Hence, we predict that affecting
either the compound binding energy or the energy of
transition to the cleaved state could affect the efficiency
of poisoning. Consistently, mutations affecting the
residues contacting compounds result in resistance to
poisoning. For instance,mutating the residues involved
in thewater–metal ion bridge results in resistance to the
FQs [29,53,54]. Moreover, mutations that affect the
transition to the cleaved state (like D83, above) confer
resistance to several different classes of gyrase poison
despite not establishing contact with them [11]. We
predict that other residues might have this property,
notably at the interface.
This model can also help to understand other facts
such as the bacterial specificity of QPT-1. Some data
suggest that the interface might be tighter in the
eukaryotic enzyme. Namely, gyrase can relax DNA
without ATP pointing to a “loose” interface. This
suggests that the energy of transition to the cleaved
state is higher for the eukaryotic enzyme and the
binding energy of QPT-1 might not be sufficient to
compensate and will not be able to poison. In other
words, when the DNA-gate closes in human type IIA
enzymes, the wedge-shaped QPT-1 can be squeezed
out of the DNA-cleavage site pocket, whereas with
bacterial type IIA topoisomerases, QPT-1 remains
trapped [10].Role of the Metal Ion at the Cleavage
Site: Dynamic Re-configuring of the
Catalytic Core
There is consensus in the literature that there are
two metal-binding sites (per catalytic pocket) in the
TOPRIM domain, about 3 Å apart. Biochemical
[55,56] and structural data [12,15,22] suggest that
in order for DNA cleavage to take place, a metal
must be making interactions with the 3′-oxygen of
the scissile phosphate. Problems in obtaining well-DNA gyrase. (A) A G-DNA segment is shown in a binary
nd. The scissile phosphate (red) is outlined on the DNA
the GyrA/GyrA’ dimer interface (red lines). (B) A T-DNA
the DNA-gate start to move, stretching the substrate gate
onfiguration, on one side. (D) The bottom strand has been
r open and a metal is captured in the A-configuration on the
re in B-configurations. (F) The T-DNA is outlined passing
nt with the scheme published by Zechiedrich et al. [49]; E is
leaved (E.S—A,B), single cleaved (E-S1—C,D) or doubly
3442 DNA Topoisomerase Inhibitorsdiffracting crystals with clear views are not uncom-
mon with type IIA topoisomerases, which can make
ascertaining the position and coordination of the
catalytic metal difficult. Therefore, we focus on
relatively high-resolution structures, which show
clear views of the coordination mode of the catalytic
metals.
As mentioned above, only gyraseCORE structures
with compounds bound and/or DNA cleaved have a
metal at the catalytic pocket. Only a single metal at
each catalytic pocket is consistently observed. The
coordination geometry is found to correlate with the
cleavage status of the DNA. In the 2.1-Å crystal
structure of GSK299423 with DNA and S. aureus
DNA gyrase (2XCS), the DNA is uncleaved at both
catalytic pockets, and a single metal ion establishes
contact with the scissile phosphate (Fig. 4, Supple-
mentary Figs. 2 and 3). The catalytic tyrosine
mutated to a phenylalanine is observed in the vicinity
pointing toward the scissile phosphate. We surmise
that this configuration is “poised” for cleavage. This
coordination configuration for the metal is dubbed
the “A-configuration” or “A-site.” Metal in the A-
configuration is coordinated by two oxygens from the
scissile phosphate, Asp508 and Glu435 from the
TOPRIM domain, and two water molecules forming
an octahedral geometry favored by the Mn2+ ion
(Fig. 5, the difference map is shown for the
coordinating oxygen, showing octahedral geometry).
Note that in the following discussion, we use the term
“configuration” to describe metal status instead of
“site” because the metal-binding site is observed in
different configurations depending on whether the
metal is at the A- or B-site. Note that a single metal,
seemingly close to the A position, is observed in a
cleaved structure (3KSA [21]). However, the resolu-
tion being lower, it is difficult to ascertain the
coordination geometry in this case. Therefore, the
status of this metal is unclear. The A-configuration is
incompatible with metal binding at the B-site and vice
versa. Super-imposing the two configurations using
as a reference the coordinating residues induces a
clash between a coordinating water molecule from
the A-configuration and the metal in the B-
configuration.
When the DNA is cleaved, the coordination of the
metal is altered and the metal is observed in the so-
called “B-configuration” or “B-site.” This is consis-
tently observed across all cleaved structures. Figure
4 shows the metal status on the highest resolution S.
aureus DNA cleavage complex structure (5CDM),
which has QPT-1 bound at pockets 1. When the
DNA is cleaved, the scissile phosphate moves away
from the metal and the metal moves to the B-site,
where it is coordinated by D508 (as in the A-
configuration), D510 and four water molecules, one
of which contacts the adjacent phosphate on the 3′-
OH side. Figure 5B shows the density of the metal
and coordinating oxygens as above. Superimposingthe two structures with D508 as a reference (more
accurately the C-Cα bond of the residual chain)
shows a rotation of the D508 residual chain that
seems to accompany the metal from the A-
configuration to the B-configuration. See also Sup-
plementary Figs. 2 and 4.
The case of the 1.98-Å GSK945237 structure [43]
is interesting. In this structure, one DNA strand is
uncleaved, while the other strand has an artificial
nick (5IWI). The electron density shows two posi-
tions for metal ions (Mn2+), one at the A-
configuration and one at the B-configuration, but
the occupancy for each metal is about 0.5. The 1.98-
Å electron density at the two active catalytic pockets
clearly shows an average of the structure seen in the
2XCS structure (with uncleaved DNA) and a second
conformation with the nicked DNA (like the 5CDM
structure, see Supplementary Fig. 2). In the crystal
structure, the asymmetric nicked DNA is bound with
a random orientation with respect to the nick,
resulting in each cleavage catalytic pocket being
an average of the cleaved and uncleaved configu-
ration in the solved structure. The 1.98-Å density
clearly shows two different configurations: a single
metal in the B-configuration when the DNA is
cleaved and a single metal in the A-configuration
when the DNA is uncleaved, averaging resulting in
the modeling of two metals with half occupancy
(Supplementary Fig. 2). The coordination geometry
of metal ion at the B configuration is consistent with
other structures with a metal at the B-configuration,
which do not display such static disorder (see
Supplementary Methods for details).
Considering all of the above, we propose a
dynamic model for the cleavage-religation cycle of
DNA gyrase (and possibly all type IIA topoisomer-
ase) in which conformational changes undergone by
the enzyme re-configure the catalytic metal coordi-
nation site in the catalytic pocket to control cleavage
and religation. Figure 7 depicts such a model. After
DNA binding, the sliding of the WHDs and the tilting
of the TOPRIM domains create a favorable coordi-
nation environment for a single metal per catalytic
pocket (the A-configuration, step 1). Contact with the
scissile phosphate allows the A-configuration metal
to catalyze phosphotransfer to the catalytic tyrosine,
the scissile phosphate moves away from the metal,
obliterating the A-configuration. The metal is then
transferred to the B-configuration (accompanied by a
rotation of Asp508, step 2) which is now more
favorable and importantly is not affected by the
opening of the DNA gate (step 3). The closure of the
DNA gate (step 4) brings the scissile phosphate in
the vicinity of the B-configuration metal and allows
the recapture of the metal by the scissile phosphate
(step 5). Irreversibility is achieved by a conforma-
tional transition to the uncleaved conformation (step
6). In this model, the enzyme controls the movement
of the scissile phosphate which, in turn, controls the
3443DNA Topoisomerase Inhibitorsmetal status and ultimately cleavage and religation.
Moving the scissile phosphate away from the metal,
which is “stored” in the B-configuration, has the
advantage of making hydrolysis of the phosphotyr-
osine bond impossible since no metal can be stably
coordinated by the enzyme around the scissile
phosphate when the DNA gate is opened. Consis-
tently in the open-gate structure obtained with
human topo II, a single metal is observed in the B-
configuration [25]. Moreover, an etoposide-bound
structure of the human enzyme also shows a single
metal in the B-configuration per catalytic pocket,
further suggesting that a single metal might be
conserved among type IIA topoisomerases.
Therefore, we surmise that what controls the
configuration of the metal coordination sphere is
the position of the scissile phosphate and preceding
phosphate. When the enzyme assumes the
“cleaved” configuration, both configurations are
possible, albeit not at the same time (see below for
further discussion). The fact that metal is observed in
the A-configuration when the DNA is not cleaved
(2XCS) suggests that the A-configuration has more
affinity than the B-configuration when the tyrosine is
mutated to a phenylalanine. When phospho-transfer
has occurred, the scissile phosphate (now bonded to
the catalytic tyrosine) moves away from D508 and
the metal moves to the B-configured site. In that
view, religation would only require the scissile
phosphate to come nearer the B-configured site
metal to recapture it by re-forming the A-configured
site. This would be consistent with the idea that the
A-configured site has more affinity. There is little
structural evidence on how this recapture would
occur. However, we suggest that the recapture can
occur through limited motion afforded by the enzyme
flexibility in this “cleaved” conformation. This is
supported by the observation that the thiophene–
gyrase–DNA complexes are a mixture of single-,
double-strand cleaved and uncleaved. This indi-
cates that the enzyme can religate even when the
“cleaved” conformation is stabilized by compounds.
There are also data suggesting that it is possible to
religate cleavage complexes while compounds are
still bound. The above considerations do not
preclude further structural controls on religation.
Indeed, it is highly likely that such control exists (see
below in the description of our model).
It is difficult to distinguish whether the metal initially
binds in the A-configuration directly or binds in the B-
configuration first and is subsequently “recruited” by
the scissile phosphate. It is expected that the A-
configuration is very transient since it leads to
cleavage. Therefore, the stable A-configuration
observed when the tyrosine is mutated by a
phenylalanine might not necessarily reflect the true
situation and is only reached when catalysis is not
possible. An alternative model might have the
scissile phosphate coming in close enough proximityto the B-configuration metal to disrupt its water
coordination, resulting in the true catalytic configu-
ration (see Supplementary Figs. 9 and 10 and
Supplementary discussion).Two-Metal versus One-Metal Cleavage
Whether two metals binding to one catalytic pocket
is necessary for cleavage remains a matter of
debate. Biochemical studies showing two different
metals can synergistically enhance cleavage rates
have been interpreted as favoring the two-metal per
catalytic pocket hypothesis [56,57]. However, we
suggest that they do not achieve this by both binding
to the same catalytic pocket [22] but rather by
cooperating in “trans,”with one in the A-configuration
on the first TOPRIM domain and the other in the B-
configuration on the second TOPRIM domain [15].
We favor the single-metal model, at least for
bacterial type IIA topoisomerases.
The electron density maps for several early low-
resolution (N3 Å) and medium-low-resolution (2.5–
3 Å) structures are not very clear [12,15,21,22,26],
and allow alternative interpretations for ligand-binding
modes and/or metal coordination geometry at the
DNA-cleavage sites to the published structure. We
have re-refined two of these structures (see Supple-
mentary Methods) to include the water–metal ion
bridge (for 2XCT) and chemically reasonable catalytic
metal coordination geometry consistent with later
higher-resolution structures: the 3.35-Å ciprofloxacin
structure 2XCT [15] and the 2.98-Å yeast topo II
structure (3L4K) [22]. With this re-refinement, all
structures, to the best of our knowledge, are consis-
tentwith a singlemetal ion in either theB-configuration
(as in the 2.16-Å crystal structure of etoposide with a
human topo II [14]) or the A-configuration (as in the
2.1-Å structure of S. aureus DNA gyrase with
GSK299423 [15]). 3L4K is the only structure in the
PDB interpreted as having two metals at a single
catalytic site at the same time. This structure is
complicated by static disorder around a crystallo-
graphic twofold axis. Single “biological” complexes
derived from the crystal structures for both the original
(3L4K) and re-refined (RR-3L4K) coordinates are
madeavailable (Table S4). The re-refined coordinates
of 3L4K are consistent with a single moving metal
mechanism for DNA cleavage by type IIA topoisome-
rases (Supplementary Fig. 5).
This being said, there are a series of arguments
that can be raised against the one-metal interpreta-
tion. First of all, the above interpretation of the two-
metal model as averaging of the two one-metal
configurations must be qualified. It is difficult to
assign occupancy unambiguously to atoms in
medium- to low-resolution structures. The hypothe-
sis of half occupancy (or for that matter full
occupancy) is therefore a choice guiding the
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that one metal only has been unambiguously
observed in a high-resolution structure (1.98 Å)
with static disorder (5IWI). The geometry modeled
in these cases is in accordance with what is known of
coordination chemistry for divalent metals. We argue
that it is therefore justified to use it as a guide to
refine low-resolution structure. However, we would
like to stress that we do not think that our refinement
of such structure settles the debate, merely that such
data could be compatible with the one-metal model.
Moreover, while our interpretation of the 5IWI
apparent two-metal density is relatively straightfor-
ward, due to the nicked DNA adopting both orienta-
tions, the case of 5CDP is not so simple. In this
structure, a doubly nicked DNA is crystallized along
with the gyraseCORE and etoposide. Only one etopo-
side molecule is observed in pocket 1, while the
symmetric pocket 1′ is free of compound. As one
would expect, according to ourmodel, onemetal in the
B-configuration is observed on the etoposide site.
However, two metals are observed on the other site,
despite theDNAbeing nicked on that side aswell. Our
interpretation is that it is due to the two configurations
coexisting in the crystal (i.e., static disorder) indepen-
dently of the symmetry axis, the relative occupancies
reflecting the respective frequency of each configura-
tion. When no compound is present, the scissile
phosphate being flexible, it can sometimes adopt a
conformation in which it can coordinate an A-
configuration metal but sometimes it does not; this
results in the metal being observed in the B-
configuration. In 5CDP, the presence of an etoposide
on the other side restricts the flexibility of the
untethered DNA, thereby allowing an A-configuration
metal at least some of the time. This is our favored
interpretation, but because the structure has static
disorder and the data only extend to 2.45-Å resolution,
other interpretations might be possible. It should be
noted, however, that the geometry of metal coordina-
tion is different in the case of 5CDP compared to
others, the presumed “A-configuration” metal being
coordinated mainly by water molecules, which are
difficult to resolve at this resolution (Supplementary
Fig. 11). The scissile phosphate is modeled by two
conformations suggesting limited flexibility. 5CDP
refinement is difficult, and therefore, any interpretation
would be subject to caution. The main point is that, in
high-resolution structures, the one-metal interpreta-
tion allows clear and unambiguous coordination
geometry (like in 5IWI).
The case of 5CDP also illustrates an argument
made by Wendorff et al. [51]. In this work, only one
metal is observed in an etoposide-bound complex. It
was proposed that this deviation from the two-metal
model is due to the compound reconfiguring the active
site and preventing the A-configuration and thereby
preventing religation. This would be a consistent
interpretation of 5CDP. In fact, our interpretation is notthat different. The idea that removing the A-
configuration metal prevents religation is not contro-
versial and actually compatible with both models. The
only difference between the two models is the source
of the metal filling the A-configuration when religation
occurs. If it comes from the solution, twometals will be
the catalytic configuration; if it is mobilized from the B-
configuration, you get the one-metal mechanism. We
think it is unlikely that the one-metal observation
results from compound reconfiguring the active site.
Several, unrelated compounds show one metal,
including the allosteric hinge binders that do not
interact with DNA. Moreover, 5CDR does not have
any compound bound and shows only one metal.
Nevertheless, crystallography always samples out
stable conformations, and it is possible that the true
catalytic configuration has not been observed, only
pre- and post-catalytic configurations are likely to be
observed. It is worth noting, however, that from
existing knowledge of phospho-transfer reactions,
only one metal is absolutely required for catalysis: the
A-configuration metal. It is not at all clear what a B-
configuration metal would do to make itself essential
for catalysis, in addition to theA-configurationmetal, in
such a way that the only catalytic configuration would
be with two metals bound. We argue that the one-
metal configuration is the minimal required for activity.
The two sites having different affinity, the configuration
could alsobedifferent dependingon the concentration
of divalent metal in the solution (or the intracellular
media).
We have used the 20-12p-8 DNA in many
unpublished crystal structures with NBTIs. When
the resolution is sufficiently high (as in the 1.98-Å
5IWI), two conformations are clearly visible in
electron density maps. However, as the resolution
becomes lower (as in the 2.45-Å 5CDP structure),
the two conformations are not always so clearly seen
in electron density maps. We have refined all
medium-high and medium-low structures consistent-
ly with our unambiguous high-resolution structures.
However, given the poor quality of the data, we
cannot be 100% certain that such structures could
not be open to other interpretations.
As a direction for future studies, we would like to
suggest trying to sample out the true catalytic
configuration using fluoride compounds of divalent
metal standing in for the scissile phosphate. This
might settle the debate, although the requirement for
high resolution might make it challenging. It is also
expected that real-time crystallography data would
shed light on the catalytic mechanism.An Integrated Model for the Strand-
Passage Reaction
In this simplified model, the catalytic cycle starts
when the G-DNA is captured. To achieve cleavage,
3445DNA Topoisomerase Inhibitorsthe DNA is then bent [26], resulting in the central four
base pairs between the two DNA-cleavage states
adopting an A-DNA like conformation. At this stage,
the distance between the two scissile phosphates is
about 21 Å (as in the binary complex, 6FQV). With
the DNA bound and the protein in this conformation,
there is no metal bound. Interestingly for yeast topo
II, Mueller-Planitz and Herschlag [58] identified two
conformations that can have G-DNA bound: the first
conformation efficiently “binds DNA at a diffusion
limited rate but cannot efficiently cleave DNA,” while
the second conformation binds (and releases) DNA
very slowly but allows DNA cleavage. Presumably,
the first conformation has the G-DNA bound but not
bent, precluding cleavage, while the second confor-
mation has the DNA bent, allowing cleavage.
However, it is also possible that the first conforma-
tion is captured by the binary complex 6FQV. There
is to date no structure with the DNA unbent. It is
expected that such a structure would be informative.
When the T-DNA has been captured by the ATPase
domains, the captured T-DNA and ATPase domains
start to try and push open the DNA-gate (Fig. 8B–F;
see also Fig. 1). Initially, this moves a TOPRIM
domain and starts to stretch the G-DNA segment
allowing a single metal to be captured (Fig. 8B). We
then envision that if metals are bound, they either are
recruited directly to the A-configuration (Figs. 7 and 8)
or normally reside in the B-configuration, unless
transiently attracted to interact with the scissile
phosphate if it comes close enough (resulting in an
A-configurationmetal, Supplementary Figs. 9 and 10).
When the metal is in the A-configuration, DNA
cleavage occurs (steps B–C Fig. 8), and the scissile
phosphate from thenowcleavedDNA (attached toTyr
A123) relaxes away from the cleavage site (Fig. 8C),
and themetal returns to theB-configuration. Onceone
strand has been cleaved and as the T-DNA pushes
the DNA-gate open, the DNA-gate will adopt an
asymmetric conformation [10] (Fig. 8D) and then the
second cleavage step will occur (Fig. 8D–E).
Deweese and Osheroff [59] state that for topo II “it is
believed that cleavage of the first stand introduces
flexibility in the DNA that allows the substrate to attain
an acutely bent transition state that is required for
efficient cleavage,” and that the rate for cleavage of
the second strand is faster than that for the first strand.
The idea of an asymmetric orientation of the T-
segment during passage is supported by some cryo-
EM work [60].
The simplified model suggests that once the T-
DNA has passed through the DNA-gate, at least one
of the DNA strands must be religated before the exit
gate can open. Mutation at the C-gate favors
cleavage in yeast topoisomerase II, and Schmidt et
al. [22] have proposed a structural model for the
coupling of cleavage to C-gate closure, which
controls the position of the tyrosine. We suggest
that, when the tyrosine is bonded to the scissilephosphate, such control could in turn influence the
position of the scissile phosphate and recapture of
the metal to achieve religation. Another layer of
control could involve the GK domain (as mentioned
above). Interestingly, in both S. aureus binary
structures (Table 1, 6FQV and 5CDR), the main-
chain N-H group of Leu583 (the L from the YKGLG
motif) is within hydrogen-bonding distance of one of
the side-chain oxygens of Asp508. However, in
5CDR (where the DNA is cleaved), the other side-
chain oxygen from Asp508 coordinates a Mn2+ ion
(whereas no metal is observed in 6FQV). This raises
the possibility of an involvement of the Greek key
fold in controlling metal coordination. We have
previously proposed [10] that the function of the
GK domain is to interact with the T-DNA and prevent
the catalytic metal in the B-configuration moving to
re-cleave the G-DNA, as the exit gate opens and the
T-DNA is released. If the exit gate opened while the
G-DNA contained a double-stranded break, this
might be potentially hazardous for the cell. We
suggest that the Greek key could exert control of the
metal position through the YKGLG motif, to which it
is directly adjacent. Whether the Greek key is
ordered or not might be associated with such control.
The presence of a single-strand cleaved interme-
diate during this cycle is evidenced by the mixture of
single- and double-strand cleavage induced by the
enzyme in the presence of ATP [16], also suggesting
that the ATP hydrolysis cycle favors the transition to
the cleaved state. The exact nature of this singly
cleaved intermediate is difficult to ascertain. Bio-
chemical and structural data show that some
asymmetry can be transiently or permanently as-
sumed by the enzyme. As discussed above, many
compounds stabilize a significant amount of single-
strand breaks as opposed to double-strand breaks
only. Etoposide and the thiophenes stabilize a
mixture of single- and double-strand breaks
[10,16], and the NBTIs only stabilize single-strand
breaks [15,52]. A single-strand intermediate is
observed during cleavage induced by the fluoro-
quinolone ciprofloxacin and also during religation of
the cleavage complex [11,61]. In addition, some
structures with asymmetry were solved (Casym
class of structure [10]). In those structures, however,
the DNA is doubly cleaved so it is difficult to correlate
the cleavage status with the structural conformation
on each site of the C2 axis. As mentioned previously,
an asymmetric DNA can be bound both ways in the
crystal, resulting in the symmetric averaging of a
potential asymmetric structure. Despite several
years of effort, we failed to obtain crystals in which
an asymmetric DNA is bound in a single orientation
[24]. To date, all structures with S. aureus DNA
gyrase with asymmetric DNAs [43] have the DNA in
two orientations related by the C2 symmetry of the
complex. The structural characterization of the
asymmetric state(s) with singly cleaved DNA
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that asymmetry in cleavage could be coupled to an
asymmetry in protein domains conformation.
Taken together, our data suggest the following
simple model for the strand passage reaction (Fig. 8):
1. Capture of G-DNA segment
2. G-DNA segment bending, no metal bound
(binary complex structure 6FQV)
3. Capture of T-DNA- segment by ATPase
domains.
This causes DNA at the gate to be stretched
through a conformational transition to the cleaved
state. The exact mechanism is unclear. This is
asymmetric since the T-segment probably does not
enter orthogonally to the G-segment [25] and causes
one metal to bind at the A-configuration on one side
only (but see Supplementary Fig. 10).
4. The metal at the first cleaved site now moves
to the B-configuration and, as the T-DNA
continues to push the DNA-gate open, the
second scissile phosphate moves close to the
TOPRIM domain, allowing cleavage of the
second DNA strand through capture of a
second metal.
5. The DNA-gate now opens as the T-DNA is
pushed downward and through.
6. Once the T-DNA has moved through, the DNA-
gate swings closed (like a swinging-door).
7. The T-DNA is now between the DNA-gate and
exit gate. The T-segment segment has then
the potential to bind one or two of the GK
domains. We hypothesize that interaction with
only one of the GK domains might underlie the
stepwise religation. This binding might influ-
ence the cleavage status through the YKGLG
motif being moved to hold the catalytic metal in
the B-configuration and to prevent the catalytic
metal moving back to the A-configuration while
the exit gate is opening. The exact nature of
this coupling is unclear.
8. The opening of the exit gate releases the T-
segment and forces religation, presumably
through the motion described in Ref. [22].Conclusions and Future Directions
The main subject of this article is the interpretation
of x-ray crystal structures of topoisomerase–DNA–
drug complexes. However, it remains difficult to
obtain high-resolution (b2-Å) x-ray crystal structures
of DNA complexes of the DNA-cleavage gate of type
IIA topoisomerases. As mentioned above, several
low- and medium-low-resolution structures with
potentially ambiguous interpretations of ligand bind-ing and/or metal coordination geometry at the DNA-
cleavage sites have been published [12,15,21,22].
Two of these have now been re-refined and the
coordinates made available.
Overall, the most parsimonious interpretation of
the current structural data is that only a single metal
ion is ever present at any one DNA-cleavage active
site at any one time. Although the possibility that two
metals could bind at one active site at the same time
cannot be ruled out, in our opinion, convincing
crystallographic evidence of this two-metal possibil-
ity has yet to be demonstrated. Despite the fact that
coordination geometry for many metal ions has been
reasonably well defined by small-molecule crystal
structures, there are a number of structures in the
PDB where the coordination geometry of the metal
binding sites does not match what has been
established with small molecules. Our single-metal
model for the cleavage–religation cycle preserves an
acceptable coordination geometry for the catalytic
metal. However, it remains to be directly tested and
the dynamics of the metal at the catalytic pocket
remain to be explored.
Based on both the crystallographic and biochem-
ical data, we have proposed two different models in
which type IIA topoisomerases control DNA cleav-
age and religation prior to and after strand
passage, respectively, through a number of con-
formational changes (Figs. 7 and 8 and Supple-
mentary Figs. 9 and 10). These changes result in
changes of DNA conformation at the cleavage
catalytic pocket, which favor the capture of a single
catalytic metal ion per catalytic pocket. The metal
status is determined by the position of the scissile
phosphate and the preceding phosphate, which
form part of the coordination site responsible for the
catalysis of the phosphotransfer reaction (the A-
configuration). The scissile phosphate moves
away when the DNA is cleaved (notably by the
opening of the DNA gate), and the metal can be
transferred to the B-configuration which indirectly
interacts with the 3´-OH side of the cleavage,
thereby keeping the catalyst with the nucleophile
needed for the reverse phophotransfer reaction
and away from any other nucleophile (like water for
instance). The enzyme controls religation by
controlling the position of the scissile phosphate,
which approaches the B-configuration metal after
closure of the DNA gate and presumably recap-
tures the catalytic metal.
In this model, the action of cleavage complex-
stabilizing compounds is twofold. First, they bind to
pockets that are only present when the enzymehas the
ability to cleave DNA. They therefore stabilize a
conformation of the enzyme in which cleavage is
rendered possible by shortening the distance between
the scissile phosphates and their cognate catalytic
pockets. This constitutes the “allosteric”modeof action.
Second, compounds can also interact directly with the
3447DNA Topoisomerase InhibitorsDNA in the central region, thereby influencing the
position of the scissile phosphate and the cleavage
status of the DNA. This explain why some compounds
stabilize variousproportionof single- anddouble-strand
breaks.
Structural biology is yet to precisely define the
domain movements associated with T-DNA segment
movement, although a number of studies have helped
define and develop current understanding of DNA
gyrase dynamics [60,62–66]. Of particular interest is
how the structural transition assumed by the enzyme
as it progresses along its DNA binding, cleavage and
religation cycle, are coupled to the transport of the T-
DNA segment across the enzyme interface and
ultimately ATP binding and hydrolysis. It is well
established that strand passage is coupled to ATP
binding and hydrolysis, although the precise mode of
this coupling is yet to be understood [67]. Consistent
with the idea that the ATP binding and hydrolysis cycle
influence the conformational changes involved in
cleavage, it was found that ATP accelerates the
appearance of cleavage induced by ciprofloxacin and
the IPY compounds [11,61]. It should be noted that T-
DNA capture is asymmetric and a sequential ATP
hydrolysismodel has been proposed for yeast topo II in
which strandpassage is coupled to thehydrolysis of the
first ATP [68–70]. It is tempting to speculate that the
asymmetry in cleavage reflects the intrinsic, and
transient, asymmetry of the strand-passage reaction.Acknowledgments
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